List of works - Marcus Hompesch

A novel insulin formulation with a more rapid onset of action.

scientific article published on 19 July 2008

Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase ⬇️

scientific article

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

scientific article published on 26 October 2014

Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

scientific article published on 01 June 2015

Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.

scientific article

Biosimilar Insulins: Basic Considerations

scientific article

Biosimilar insulins: guidance for data interpretation by clinicians and users

scientific article

Biosimilar insulins: how similar is similar?

scientific article

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

scientific article published on 8 February 2012

Capillary and venous blood glucose concentrations measured during intravenous insulin and glucose infusion: a comparison of steady and dynamic states

scientific article published in October 2009

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

scientific article published on 04 June 2013

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

scientific article published in January 2011

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase

scientific article published on 5 October 2012

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

scientific article published on 27 May 2010

Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor

scientific article published on 7 February 2011

Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm

scientific article published on 01 September 2012

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin

scientific article published on 3 July 2014

Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range

scientific article

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

scientific article

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

scientific article published in September 2006

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.

scientific article

Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.

scientific article

Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase

scientific article published on 2 December 2011

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials

scientific article published on 02 December 2020

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection

scientific article published on 28 February 2011

Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin

scientific article

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

scientific article

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

scientific article published in PLoS ONE

Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus

scientific article published on 5 February 2014

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

scientific article published on 12 October 2011

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

scientific article published in November 2009

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.

scientific article published on 29 June 2011

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin

scientific article

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

scientific article published on 9 June 2014

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

scientific article published on 31 July 2012

Short-term metabolic effects of prednisone administration in healthy subjects

scientific article published on 01 November 2011

Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action

scientific article

Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?

scientific article published on 01 October 2013

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

scientific article published in September 2006

alpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathy

scientific article published on 01 December 1997

List of works by Marcus Hompesch

A novel insulin formulation with a more rapid onset of action.

Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase ⬇️

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.

Biosimilar Insulins: Basic Considerations

Biosimilar insulins: guidance for data interpretation by clinicians and users

Biosimilar insulins: how similar is similar?

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

Capillary and venous blood glucose concentrations measured during intravenous insulin and glucose infusion: a comparison of steady and dynamic states

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor

Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin

Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.

Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.

Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection

Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

Short-term metabolic effects of prednisone administration in healthy subjects

Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action

Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

alpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathy